NVNishant Verma

Nishant Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nishant Verma has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating STAT3 and SMAD1/SMAD4 with Hepcidin Levels Across β-Thalassemia Subtypes: A Cross-Sectional Study

    by Kirti Upadhyay, Nitu Nigam, Swasti Sinha, Nishant Verma, Suresh Chand, Anshul Gupta, Soniya Nityanand

    Background/Objectives: The background of the research shows that β-thalassemia is a hemoglobinopathy which is characterized by ineffective erythropoiesis and iron overload and this is kept in balance by hepcidin hormone due to BMP/SMAD and JAK/STAT3 pathways. However, it is not known how exactly these signaling pathways are involved in iron metabolism disorders for different forms of β-thalassemia, therefore, the aim of the present research was to analyze circulating levels of hepcidin, STAT3, SMAD1 and SMAD4 in participants with β-thalassemia and evaluate their exploratory discriminatory potential. Methods: The methodology of the research includes a comparative cross-sectional study of 135 patients with β-thalassemia major, intermedia and minor, as well as healthy control individuals based on hemoglobinopathy typing with the high-performance liquid chromatography. The circulating hepcidin levels, SMAD1 and SMAD4 concentrations as well as plasma STAT3 levels were identified and measured by ELISA method. Statistical processing methods include one-way ANOVA, multinomial logistic regression and ROC curve analysis based on ten-fold cross-validation. Results: Hepcidin and SMAD1 levels showed heterogeneity among groups, whereas differences in STAT3 and SMAD4 were not statistically significant. In multinomial logistic regression, lower hepcidin was associated with β-thalassemia major and lower SMAD1 with β-thalassemia intermedia. ROC analysis showed moderate in-sample discrimination for hepcidin and stronger discrimination for SMAD1. Conclusions: Altered circulating hepcidin and SMAD1 patterns may reflect dysregulation of BMP-SMAD/hepcidin signaling across β-thalassemia subtypes. These findings are exploratory and require independent validation before clinical application.

  • Open Access

    Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants

    by Songa Narayana Rao, Deepali Ambike, Mahantesh Patil, Sanjay Vasant Mankar, Nishant Verma, Neeta Hanumante, Lisa Sarangi, Monjori Mitra, Godatwar Preeti, Bhaskar Jedhe Deshmukh, et al.

    Typhoid fever, measles, and rubella continue to contribute significantly to childhood morbidity and mortality in India. In line with WHO recommendations for co-administration of Typhoid Conjugate Vaccine (TCV) and measles–rubella (MR) vaccine at 9 months of age, this phase IV, randomized, open-label, multicenter clinical trial was conducted to assess their immunological compatibility and safety when administered concomitantly. A total of 900 healthy Indian infants aged 9–10 months were randomized into three groups: Group A received TCV and MR vaccine concomitantly; Group B received MR on Day 0 and TCV on Day 28; Group C received TCV on Day 0 and MR on Day 28. Subjects were followed for 6 months after concomitant/last vaccination. Seroconversion rates (SC) in Groups A/B/C at Day 28 were 90.2%/75.3%/89.5% for anti-Vi; 80.4%/75.2%/77.7% for anti-measles, and 87.7%/84.0%/85.2% for anti-rubella antibodies. By study end, SC for anti-Vi was 87.1%/71.6%/83.0%, while SC for anti-measles and anti-rubella reached ~90% and ≥98%, respectively, across all groups. Geometric mean titers increased significantly for all antigens, with no evidence of immunological interference. Safety assessments showed adverse events in 23.9%/32.0%/32.7% participants in Group A/B/C. Most adverse events were mild, and only one serious adverse event was reported. These findings support the co-administration of TCV and MR vaccine as a safe and effective strategy.

  • Open Access

    Sanger Sequencing of Exon 14 of RB1 Gene Among North Indian Children with Retinoblastoma

    by Honey Zahra, Sushma Tomar, Nikhil Aggarwal, Nishant Verma, Syed Tasleem Raza, Sanjiv Kumar Gupta, Rakesh Kumar Verma, Punita Manik

    Introduction: The RB1 gene has been studied for decades. A large number of genetic analytical studies on this gene are published in the Western world, but very few studies from India are available online. RB1 is the most critical gene involved in the causation of retinoblastoma, and Exon 14 is one of the highly mutated exons of this gene. Aim: To discover the genetic variants in Exon 14 of the RB1 gene in North Indian retinoblastoma patients. Materials and Methods: This was an inter- and intra-institutional cross-sectional observational study. The Department of Anatomy, Ophthalmology, and Paediatrics at King George’s Medical University UP, Lucknow, collaborated with the Department of Biochemistry, ERA University, Lucknow. After obtaining written informed consent from their parents or legal guardians, 40 clinically and radiologically diagnosed retinoblastoma patients were included as study participants. The age range was 12-84 months. 2 ml of peripheral venous blood was withdrawn from 29 patients, and we obtained tumour tissue from 14 patients. We isolated the genomic DNA, which was amplified by PCR, and the amplified products were sent for Sanger sequencing. Chromatograms were analyzed using the BioEdit software. Results: Most patients (92.5%) were below five years of age. Male preponderance was seen, as there were 37.5% females and 62.5% males. In the majority of cases (72.5%), the tumor was seen unilaterally with predominant involvement of the right eye; while in 27.5% of cases, both eyes were seen affected. We did not observe any variations in the sequences of exon 14. Conclusions: As the RB1 gene has 27 exons, therefore screening for mutations in all exons is required to reach a concrete conclusion. Genetic variants might be located in the intronic regions, which may affect the proper functioning of the RB1 gene; therefore, sequencing of the entire gene will be more helpful. Next Generation Sequencing (NGS) is preferred because of the large size of the gene. KEYWORDS: Retinoblastoma, DNA, PCR, RB1 gene, sequencing.

  • Open Access

    Extraocular and metastatic retinoblastoma: A problem of low-middle income countries

    by Amita Mahajan, Rolika Bansal, Rachna Meel, Sima Das, Kasturi Bhattacharjee, Devjyoti Tripathy, Usha Singh, Nishant Verma, Parag Shah, Mobashir Sarfraz Ali, et al.

  • Open Access

    Clinical spectrum and prognostic markers of multi-system inflammatory syndrome in children hospitalised in Northern India

    by Areesha Alam, Nishant Verma, Shally Awasthi, Dipti Agarwal, Krishna Kumar Yadav, Pradeep Kumar Gupta, Ranjeeta Dadoria, Anita Mehta, Kuldeep Singh, Moinak Sen Sarma, et al.


  • Response assessment by positron emission tomography‐computed tomography as compared with contrast‐enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low‐ and middle‐income countries

    by Manas Kalra, Sameer Bakhshi, M. Singh, Rachna Seth, Nishant Verma, Sandeep Jain, V. Radhakrishnan, Piali Mandal, Amita Mahajan, Ramandeep S. Arora, et al.

    Introduction: The InPOG‐HL‐15‐01, a multicentric prospective study, used a risk‐stratified and response‐based approach with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) backbone to treat children and adolescents with newly diagnosed Hodgkin lymphoma (HL) and reduce the use of radiation therapy (RT). Children/adolescents with bulky disease or inadequate response at early response assessment (ERA) after two cycles of chemotherapy were assigned to receive RT. For ERA, positron emission tomography computed tomography (PET‐CT) was recommended but not mandatory in view of limited access. This study aimed to compare the impact of using contrast‐enhanced computed tomography (CECT) and PET‐CT on treatment decisions and outcomes.Methodology: 396 patients were enrolled and 382 had an ERA at the assigned time point. Satisfactory response was defined as Deauville score 3 or less for patients undergoing PET‐CT and complete response (CR)/very good partial response (VGPR) for patients undergoing CECT. Outcomes of interest incorporate 5 year event‐free survival (EFS), EFS including abandonment (EFSa), and overall survival (OS).Results: At ERA, satisfactory response was documented in 277 out of 382 (72.5%) participants and this was significantly higher in PET‐CT (151 out of 186, 81.2%) as compared with CECT‐based assessments (126 out of 196, 64.3%) respectively (p value < .001). Amongst the 203 patients with nonbulky disease (wherein the indication for RT was entirely dependent on ERA), 96 out of 114 (84.2%) and 61 out of 89 (68.5%) patients achieved a satisfactory response according to the PET‐CT and CECT (p value = .008) respectively and hence a lesser proportion of patients in the PET‐CT arm received RT. Despite a lower usage of RT the 5 year OS of both groups, ERA based on CECT (91.8%) versus PET‐CT (94.1%) was comparable (p value = .391) and so was the 5 year EFS (86.7 vs. 85.5%, p value = .724).Conclusion: Use of PET‐CT as the modality for ERA is more likely to indicate a satisfactory response as compared with CECT and thereby decreases the need for RT in response‐based treatment algorithm for HL‐afflicted children. The reduction in the application of RT did not impact the overall outcome and plausibly would lower the risk of delayed toxic effects.


  • Open Access

    Bleeding Versus Thrombotic Tendency in Young Children With Beta-Thalassemia Major

    by Shalini Singh, Geeta Yadav, Rashmi Kushwaha, Mili Jain, Wahid Ali, Nishant Verma, Shailendra P. Verma, U. S. Singh

    Bleeding and thrombotic events are known to occur in beta-thalassemia major (BTM) patients and have been attributed to hepatic iron overload associated with multiple blood transfusions. We evaluated hemostatic parameters in children with BTM who had no previous history of bleeding or thrombotic episodes. Hemostatic parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), platelet aggregation, protein C and S, iron profile, and liver function tests were evaluated in 54 children (median age = 12 months, age range = 4-144 months) with BTM and 15 age and sex-matched controls. The mean PT and APTT of patients were significantly higher (P=0.016 and P <.001) than that of controls. Mean protein C, protein S activity and platelet aggregability with adenosine 5-diphosphate (ADP) as an agonist in patients were significantly lower (P <.001, P <.001 and P=0.007, respectively) than that in controls. Mean serum ferritin in BTM children was not significantly elevated to be associated with hepatic dysfunction. Deranged hemostatic parameters indicative of bleeding and thrombotic tendencies are observed in BTM children from an early age and may not be solely due to hyperferritinemia-associated hepatic dysfunction. Despite the presence of deranged hemostatic parameters, a state of balance exists between bleeding and thrombosis, and an imbalance may lead to bleeding or thrombotic events at a later age.


  • Open Access

    The impact of COVID‐19 pandemic on access to treatment for children with cancer in India and treating center practices

    by Jyotsna Sharma, Amita Mahajan, Sameer Bakhshi, Veerendra Patil, Nishant Verma, Venkatraman Radhakrishnan, Amitabh Singh, Smita Kayal, Rachna Seth, Deepam Pushpam, et al.

    Background: The coronavirus disease 2019 (COVID‐19) pandemic led the Indian government to announce a nationwide lockdown on March 23, 2020. This study aimed to explore the impact of the pandemic on the accessibility of care for children with cancer and to view strategies adopted by hospitals for service delivery.Methods: Weekly average of childhood cancer (≤18 years) patient registrations during pre‐lockdown period (January 1 to March 23, 2020) were compared with post‐lockdown period (March 24 to May 31, 2020). The effect on the scheduled treatment was investigated for post‐lockdown period. A survey of health care providers was conducted to determine centers' adopted strategies.Results: In 30 participating centers, 1146 patients with childhood cancer (797 pre‐lockdown period and 349 post‐lockdown period) were registered. The weekly average registration was 67.3 and 35.5 patients during pre‐lockdown and post‐lockdown respectively (decline of 47.9%). Although most centers experienced this decline, there were 4 that saw an increase in patient registrations. The distribution of patients registered post‐lockdown was found significantly different by age (lesser older age,P= .010) and distance (lesser travel distance,P= .001). 36.1% of patients, who were scheduled for any of the treatment modalities (chemotherapy, surgery, radiotherapy, and hematopoietic stem cell transplantation) during the post‐lockdown period, experienced delays. Centers adopted several strategies including modifications to treatment protocols, increased use of growth factors, and increased support from social organizations.Conclusions: This multicenter study from India suggests that the COVID‐19 pandemic and the lockdown impacted 2 out of 3 children with cancer. The effect of this on survival is yet to be established.